Geneva, Sept. 21 -- International Clinical Trials Registry received information related to the study (ChiCTR2600132284) titled 'Low-dose interleukin-2 (IL-2) treatment for anti-IFN-? autoantibody syndrome (AIGAs syndrome): A prospective self-control study' on Sept. 11.
Study Type: Interventional study
Study Design:
Single arm
Primary Sponsor: The First Affiliated Hospital of Guangxi Medical University
Condition:
Anti-?-interferon autoantibody syndrome
Recruitment Status: Recruiting
Phase: N/A
Date of First Enrollment: 2025-08-19
Target Sample Size: Intervention group:20;
Countries of Recruitment:
China
To know more, visit https://www.chictr.org.cn/showproj.html?proj=284233
Disclaimer: Curated by HT Syndication....